This company has been marked as potentially delisted and may not be actively trading.

Intercept Pharmaceuticals (ICPT) Competitors

ICPT vs. BCRX, CLDX, INVA, NVAX, and ZBIO

Should you be buying Intercept Pharmaceuticals stock or one of its competitors? The main competitors of Intercept Pharmaceuticals include BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

How does Intercept Pharmaceuticals compare to BioCryst Pharmaceuticals?

Intercept Pharmaceuticals (NASDAQ:ICPT) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

: BioCryst Pharmaceuticals has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intercept Pharmaceuticals $285.71M 2.78 $221.82M -$1.48 N/A
BioCryst Pharmaceuticals $874.84M 2.62 $263.86M $1.20 7.53
: Intercept Pharmaceuticals has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
: BioCryst Pharmaceuticals has a consensus price target of $19.64, suggesting a potential upside of 117.46%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Intercept Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intercept Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
BioCryst Pharmaceuticals
0 Sell rating(s)

3 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.77
: In the previous week, BioCryst Pharmaceuticals had 8 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 8 mentions for BioCryst Pharmaceuticals and 0 mentions for Intercept Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.49 beat Intercept Pharmaceuticals' score of 0.30 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
Intercept Pharmaceuticals Neutral
BioCryst Pharmaceuticals Neutral
: BioCryst Pharmaceuticals has a net margin of 30.16% compared to Intercept Pharmaceuticals' net margin of -19.39%. Intercept Pharmaceuticals' return on equity of -77.48% beat BioCryst Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Intercept Pharmaceuticals -19.39% -77.48% -11.99%
BioCryst Pharmaceuticals 30.16% -84.33% 61.35%
: 83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 6.2% of Intercept Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intercept Pharmaceuticals	$285.71M	2.78	$221.82M	-$1.48	N/A
BioCryst Pharmaceuticals	$874.84M	2.62	$263.86M	$1.20	7.53

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intercept Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.77

Company	Overall Sentiment
Intercept Pharmaceuticals	Neutral
BioCryst Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Intercept Pharmaceuticals	-19.39%	-77.48%	-11.99%
BioCryst Pharmaceuticals	30.16%	-84.33%	61.35%

Summary

BioCryst Pharmaceuticals beats Intercept Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Intercept Pharmaceuticals compare to Celldex Therapeutics?

Intercept Pharmaceuticals (NASDAQ:ICPT) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

: Celldex Therapeutics has a net margin of 0.00% compared to Intercept Pharmaceuticals' net margin of -19.39%. Celldex Therapeutics' return on equity of -41.67% beat Intercept Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Intercept Pharmaceuticals -19.39% -77.48% -11.99%
Celldex Therapeutics N/A -41.67% -38.86%
: Intercept Pharmaceuticals has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.
: Celldex Therapeutics has a consensus price target of $46.36, suggesting a potential upside of 36.93%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Intercept Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intercept Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Celldex Therapeutics
1 Sell rating(s)

1 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.83
: Intercept Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intercept Pharmaceuticals $285.71M 2.78 $221.82M -$1.48 N/A
Celldex Therapeutics $1.54M 1,725.76 -$258.76M -$3.89 N/A
: In the previous week, Celldex Therapeutics had 1 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 1 mentions for Celldex Therapeutics and 0 mentions for Intercept Pharmaceuticals. Celldex Therapeutics' average media sentiment score of 1.15 beat Intercept Pharmaceuticals' score of 0.30 indicating that Celldex Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Intercept Pharmaceuticals Neutral
Celldex Therapeutics Positive
: 83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. 6.2% of Intercept Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Intercept Pharmaceuticals	-19.39%	-77.48%	-11.99%
Celldex Therapeutics	N/A	-41.67%	-38.86%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intercept Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intercept Pharmaceuticals	$285.71M	2.78	$221.82M	-$1.48	N/A
Celldex Therapeutics	$1.54M	1,725.76	-$258.76M	-$3.89	N/A

Company	Overall Sentiment
Intercept Pharmaceuticals	Neutral
Celldex Therapeutics	Positive

Summary

Celldex Therapeutics beats Intercept Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Intercept Pharmaceuticals compare to Innoviva?

Innoviva (NASDAQ:INVA) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

: Innoviva has a net margin of 65.92% compared to Intercept Pharmaceuticals' net margin of -19.39%. Innoviva's return on equity of 37.63% beat Intercept Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Innoviva 65.92% 37.63% 23.60%
Intercept Pharmaceuticals -19.39% -77.48% -11.99%
: Innoviva has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
: Innoviva presently has a consensus target price of $34.80, suggesting a potential upside of 53.64%. Given Innoviva's stronger consensus rating and higher possible upside, equities research analysts plainly believe Innoviva is more favorable than Intercept Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innoviva
1 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.57
Intercept Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Innoviva has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innoviva $411.33M 4.08 $271.17M $3.05 7.43
Intercept Pharmaceuticals $285.71M 2.78 $221.82M -$1.48 N/A
: In the previous week, Innoviva had 5 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 5 mentions for Innoviva and 0 mentions for Intercept Pharmaceuticals. Innoviva's average media sentiment score of 0.70 beat Intercept Pharmaceuticals' score of 0.30 indicating that Innoviva is being referred to more favorably in the media.
Company Overall Sentiment
Innoviva Positive
Intercept Pharmaceuticals Neutral
: 99.1% of Innoviva shares are held by institutional investors. Comparatively, 83.8% of Intercept Pharmaceuticals shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 6.2% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	65.92%	37.63%	23.60%
Intercept Pharmaceuticals	-19.39%	-77.48%	-11.99%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Intercept Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.08	$271.17M	$3.05	7.43
Intercept Pharmaceuticals	$285.71M	2.78	$221.82M	-$1.48	N/A

Company	Overall Sentiment
Innoviva	Positive
Intercept Pharmaceuticals	Neutral

Summary

Innoviva beats Intercept Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does Intercept Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

: Novavax presently has a consensus target price of $11.88, suggesting a potential upside of 46.75%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than Intercept Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax
3 Sell rating(s)
2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.20
Intercept Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Novavax has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novavax $1.12B 1.18 $440.30M $2.41 3.36
Intercept Pharmaceuticals $285.71M 2.78 $221.82M -$1.48 N/A
: In the previous week, Novavax had 7 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 7 mentions for Novavax and 0 mentions for Intercept Pharmaceuticals. Novavax's average media sentiment score of 0.78 beat Intercept Pharmaceuticals' score of 0.30 indicating that Novavax is being referred to more favorably in the media.
Company Overall Sentiment
Novavax Positive
Intercept Pharmaceuticals Neutral
: 53.0% of Novavax shares are held by institutional investors. Comparatively, 83.8% of Intercept Pharmaceuticals shares are held by institutional investors. 1.0% of Novavax shares are held by insiders. Comparatively, 6.2% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Novavax has a net margin of 39.19% compared to Intercept Pharmaceuticals' net margin of -19.39%. Intercept Pharmaceuticals' return on equity of -77.48% beat Novavax's return on equity.
Company Net Margins Return on Equity Return on Assets
Novavax 39.19% -673.17% 43.53%
Intercept Pharmaceuticals -19.39% -77.48% -11.99%
: Novavax has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Intercept Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.18	$440.30M	$2.41	3.36
Intercept Pharmaceuticals	$285.71M	2.78	$221.82M	-$1.48	N/A

Company	Overall Sentiment
Novavax	Positive
Intercept Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Novavax	39.19%	-673.17%	43.53%
Intercept Pharmaceuticals	-19.39%	-77.48%	-11.99%

Summary

Novavax beats Intercept Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Intercept Pharmaceuticals compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

: Zenas BioPharma currently has a consensus target price of $44.14, suggesting a potential upside of 112.63%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, research analysts clearly believe Zenas BioPharma is more favorable than Intercept Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zenas BioPharma
2 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.44
Intercept Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Intercept Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zenas BioPharma $10M 119.10 -$377.74M -$7.81 N/A
Intercept Pharmaceuticals $285.71M 2.78 $221.82M -$1.48 N/A
: In the previous week, Zenas BioPharma had 11 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 11 mentions for Zenas BioPharma and 0 mentions for Intercept Pharmaceuticals. Zenas BioPharma's average media sentiment score of 1.33 beat Intercept Pharmaceuticals' score of 0.30 indicating that Zenas BioPharma is being referred to more favorably in the media.
Company Overall Sentiment
Zenas BioPharma Positive
Intercept Pharmaceuticals Neutral
: 83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 6.2% of Intercept Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Zenas BioPharma has a net margin of 0.00% compared to Intercept Pharmaceuticals' net margin of -19.39%. Intercept Pharmaceuticals' return on equity of -77.48% beat Zenas BioPharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Zenas BioPharma N/A -85.64% -61.86%
Intercept Pharmaceuticals -19.39% -77.48% -11.99%
: Zenas BioPharma has a beta of -0.61, meaning that its stock price is 161% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Intercept Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	119.10	-$377.74M	-$7.81	N/A
Intercept Pharmaceuticals	$285.71M	2.78	$221.82M	-$1.48	N/A

Company	Overall Sentiment
Zenas BioPharma	Positive
Intercept Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-85.64%	-61.86%
Intercept Pharmaceuticals	-19.39%	-77.48%	-11.99%

Summary

Zenas BioPharma beats Intercept Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Intercept Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICPT vs. The Competition

Export

Metric	Intercept Pharmaceuticals	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$794.77M	$451.91M	$6.25B	$11.77B
Dividend Yield	N/A	3.86%	2.74%	5.26%
P/E Ratio	-12.84	4.14	29.25	27.07
Price / Sales	2.78	6,879.71	504.14	75.42
Price / Cash	N/A	13.13	43.30	53.90
Price / Book	11.05	77.74	9.67	6.69
Net Income	$221.82M	-$96.07M	$3.55B	$332.64M

Intercept Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICPT Intercept Pharmaceuticals	N/A	$19.00 flat	N/A	N/A	$794.77M	$285.71M	N/A	341
BCRX BioCryst Pharmaceuticals	3.7647 of 5 stars	$9.03 -1.8%	$19.64 +117.5%	N/A	$2.29B	$874.84M	7.53	530	News Coverage Upcoming Earnings
CLDX Celldex Therapeutics	2.8122 of 5 stars	$33.86 +3.3%	$46.36 +36.9%	N/A	$2.25B	$1.55M	N/A	150
INVA Innoviva	3.5826 of 5 stars	$22.65 -1.5%	$34.80 +53.6%	N/A	$1.68B	$411.33M	7.43	100	Upcoming Earnings
NVAX Novavax	2.645 of 5 stars	$8.09 +0.8%	$11.88 +46.7%	N/A	$1.33B	$1.12B	3.36	1,990	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICPT) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intercept Pharmaceuticals (ICPT) Competitors

ICPT vs. BCRX, CLDX, INVA, NVAX, and ZBIO

How does Intercept Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Intercept Pharmaceuticals compare to Celldex Therapeutics?

Summary

How does Intercept Pharmaceuticals compare to Innoviva?

Summary

How does Intercept Pharmaceuticals compare to Novavax?

Summary

How does Intercept Pharmaceuticals compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICPT vs. The Competition

Intercept Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intercept Pharmaceuticals (ICPT) Competitors

ICPT vs. BCRX, CLDX, INVA, NVAX, and ZBIO

How does Intercept Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Intercept Pharmaceuticals compare to Celldex Therapeutics?

Summary

How does Intercept Pharmaceuticals compare to Innoviva?

Summary

How does Intercept Pharmaceuticals compare to Novavax?

Summary

How does Intercept Pharmaceuticals compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICPT vs. The Competition

Intercept Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools